A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

NCT ID: NCT03192345

Last Updated: 2024-08-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 161 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-06-09
• Study Completion Date: 2022-01-17

Brief Summary

Primary Objectives:

Dose escalation (Part 1)

Part 1A (SAR439459 monotherapy)

• To determine the maximum tolerated dose (MTD) and/or maximum administered dose (MAD) of SAR439459 when administered intravenously as monotherapy in adult patients with advanced solid tumors.

Part 1B (SAR439459 and cemiplimab combination therapy)

• To determine the MTD and/or MAD of SAR439459 administered intravenously in combination with cemiplimab administered intravenously in adult patients with advanced solid tumors.

Dose expansion (Part 2)

Part 2A (SAR439459 monotherapy)

• To determine optimal dose of SAR439459 administered intravenously in adult patients with advanced melanoma who have failed a prior therapy based on anti-PD-1 (programmed cell death-1) or anti-PD-L1.

Part 2B (SAR439459 and cemiplimab combination therapy)

• To determine the objective response rate (ORR) of SAR439459 in combination with cemiplimab in adult patients with selected advanced solid tumors by evaluation of antitumor response according to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1).

Secondary Objectives:

• Pharmacokinetic (PK) profile SAR439459 monotherapy and combined with cemiplimab, PK profile of cemiplimab combined with SAR439459.
• Immunogenicity of SAR439459 monotherapy and combined with cemiplimab.

Dose escalation (Part 1)

• Overall safety/tolerability profile of SAR439459 monotherapy and combined with cemiplimab.
• Preliminary recommended phase 2 dose (pRP2D) of SAR439459 as monotherapy or combined with cemiplimab.

Dose expansion (Part 2)

• Progression free survival (PFS), time to progression (TTP), ORR, and safety of SAR439459 as monotherapy and PFS, TTP, duration of response (DOR), disease control rate (DCR) and safety in combination with cemiplimab.
• To confirm the optimal dose of SAR439459 administered in combination with cemiplimab.

Detailed Description

The duration of the study for an individual patient will start from the signature of the main informed consent and include a screening period of up to 4 weeks (28 days), a treatment period of at least 1 or 2 cycles (21 or 14 days per cycle, respectively), an end-of-treatment visit at least 30 days following the last administration of study drug (or until the patient receives another anticancer therapy, whichever is earlier), and a follow-up visit 3 months after treatment discontinuation and every 3 months following, until disease progression, or initiation of another antitumor treatment, or death, whichever is earlier. For the urothelial cancer cohort in Part 2B, follow-up visits will occur every 3 months until death, study cut-off date, or upon cancellation of Survival follow-up at the discretion of the Sponsor at any prior timepoint. For the overall survival analysis (approximately 12 months after last patient first dose), whichever comes first.

Patients who have no disease progression, and continue to benefit from the study drug(s), will be allowed to continue treatment beyond the common study end-date at their assigned dose unless the study is terminated by the Sponsor. The expected enrollment period is approximately 42 months.

Conditions

Malignant Solid Tumor

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dose Escalation SAR439459 monotherapy

SAR439459 administered intravenously every 2 weeks in a 14-day cycle with escalating doses

Group Type: EXPERIMENTAL

SAR439459

Intervention Type: BIOLOGICAL

Pharmaceutical form: powder for solution for infusion

Route of administration: intravenous infusion

Dose Expansion SAR439459 monotherapy

SAR439459 administered intravenously every 3 weeks in a 21-day cycle with the previously determined recommended doses as the patients will be randomized to 2 different doses

Group Type: EXPERIMENTAL

SAR439459

Intervention Type: BIOLOGICAL

Pharmaceutical form: powder for solution for infusion

Route of administration: intravenous infusion

Dose Escalation SAR439459 + cemiplimab combination

SAR439459 + cemiplimab combination administered intravenously every 2 weeks in a 14-day cycle or every 3 weeks in a 21-day cycle with escalating SAR439459 doses and cemiplimab

Group Type: EXPERIMENTAL

SAR439459

Intervention Type: BIOLOGICAL

Pharmaceutical form: powder for solution for infusion

Route of administration: intravenous infusion

Cemiplimab REGN2810

Intervention Type: DRUG

Pharmaceutical form: solution for infusion

Route of administration: intravenous infusion

Dose Expansion SAR439459 + cemiplimab combination

SAR439459 + cemiplimab combination administered intravenously every 3 weeks in a 21-day cycle with previously determined SAR439459 doses and cemiplimab

Group Type: EXPERIMENTAL

SAR439459

Intervention Type: BIOLOGICAL

Pharmaceutical form: powder for solution for infusion

Route of administration: intravenous infusion

Cemiplimab REGN2810

Intervention Type: DRUG

Pharmaceutical form: solution for infusion

Route of administration: intravenous infusion

Interventions

SAR439459

Pharmaceutical form: powder for solution for infusion

Route of administration: intravenous infusion

Intervention Type: BIOLOGICAL

Cemiplimab REGN2810

Pharmaceutical form: solution for infusion

Route of administration: intravenous infusion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Dose escalation (Part 1A and Part 1B)

• Patients with histologically confirmed, advanced unresectable or metastatic solid tumor whom in the opinion of the Investigator does not have a suitable alternative therapy.

Dose expansion (Part 2A)

• Patients with histologically confirmed, advanced unresectable or metastatic melanoma whom in the opinion of the Investigator does not have a suitable alternative therapy.
• Patients must have failed after any prior therapy based on anti-PD-1 or anti-PD-L1 as defined by disease progression within 26 weeks of initiating anti-PD-1 or anti-PD-L1 based therapy without any evidence of a response (primary resistance to anti-PD-1 or anti-PD-L1).
• Patients must have a site of disease amenable to biopsy and be a candidate for tumor biopsy. Patients must be able and willing to provide mandatory tumor biopsies prior to and during study treatment.

Dose expansion (Part 2B)

• Patients with disease location amenable to mandatory tumor biopsy at baseline with histologically confirmed advanced unresectable or metastatic melanoma, colorectal adenocarcinoma, urothelial cancer, hepatocellular carcinoma (HCC), or non-small cell lung cancer (NSCLC).
• Melanoma patients must have failed one prior therapy based on anti-PD-1 or anti-PD-L1.
• Patients with colorectal cancer must have progressed after last line of therapy.
• Patients with urothelial cancer must have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Patients must not have received >2 lines of therapy for advanced disease. Patients must not have received prior treatment with anti-PD-1 or anti-PD-L1.
• Patients with HCC must have failed after 1 prior therapy based on anti-PD-1 or anti-PD-L1.
• Patients with NSCLC must have failed during or after 1 prior therapy based on anti-PD-1 or anti-PD-L1.
• Patients with histologically confirmed, advanced unresectable or metastatic melanoma, or colorectal cancer or NSCLC whom in the opinion of the Investigator do not have a suitable alternative therapy.

Dose expansion parts 2A and 2B

• At least 1 measurable lesion by RECIST v1.1.

All cohorts

• Patient understands and has signed Informed Consent form and is willing and able to comply with the requirements of the trial.

Exclusion Criteria

• Age <18 years or < the country's legal age of majority if the legal age is more than 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status >1.
• Concurrent treatment with any other anticancer therapy (including radiotherapy or investigational agents) or participation in another clinical study.
• Washout period of less than 3 weeks to prior anticancer therapy.
• Women of reproductive potential and male subjects with female partners of childbearing potential who are not willing to avoid pregnancy by using highly effective contraceptive.
• Pregnant or breast-feeding women.
• Unwillingness and inability to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.
• Significant and uncontrolled concomitant illness, including any psychiatric condition.
• Active infections, including unexplained fever (temperature >38.1ºC), or antibiotic therapy within 1 week prior to enrollment.
• Any prior organ transplant including allogeneic bone marrow transplant.
• History within the last 5 years of an invasive malignancy other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment.
• History of known human immunodeficiency virus (HIV), HIV serology at screening will be conducted only for patients in German study sites.
• Known uncontrolled hepatitis B virus (HBV) infection.
• Known untreated current hepatitis C virus (HCV) infection.
• Any major surgery within the last 28 days.
• Patients with primary central nervous system (CNS) tumors and/or CNS metastases of non-CNS primary tumors.
• History of congestive heart failure, myocardial infarction with reduced ejection fraction, symptomatic coronary artery disease, documented uncontrolled hypertension, major clinically significant Electrocardiography (ECG) and echocardiogram abnormalities, significant ventricular arrhythmias, significant valvular heart disease (including valve replacement), vascular malformation, aneurysm, significant pulmonary conditions such as idiopathic pulmonary hypertension, uncontrolled chronic lung disease.
• History of severe, acute or chronic renal diseases.
• Any of the following within 6 months prior to study enrollment: pulmonary embolism, deep vein thrombosis, active uncontrolled bleeding, infectious or inflammatory bowel disease, diverticulitis, intestinal obstruction or perforation and gastrointestinal hemorrhage.
• Inadequate hematological, renal or liver function.
• Non-resolution of any prior treatment related toxicity to Grade <2.
• Prior treatment with any anti-transforming growth factor β (anti-TGFβ) inhibitors.
• Known allergies to any component of SAR439459 and/or cemiplimab.
• Patients with uveal melanoma and patients with prior or ongoing uveitis.
• Patients who received prior immunotherapy who developed toxicity leading to a permanent discontinuation of immunotherapy.
• Ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments.
• Immunosuppressive corticosteroid doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of SAR439459 and/or cemiplimab (occasional use of inhaled, intraocular, nasal or topical steroids for symptomatic relief allowed).
• History of interstitial lung disease or active non-infectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management.
• Patients with underlying cancer predisposition syndromes.
• Receipt of a live vaccine within 30 days of planned start of study medication.
• Therapeutic doses of anticoagulants or antiplatelet agents within 7 days prior the first dose of SAR439459.
• Prothrombin time (PT) or international normalized ratio (INR) > 1.5 × upper limit of normal (ULN).
• Patients accommodated in an institution because of regulatory or legal order; prisoners or patients who are legally institutionalized.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi

Locations

The University of Kansas Clinical Research Center Site Number : 8400004

Fairway, Kansas, United States

Massachusetts General Hospital Site Number : 8400001

Boston, Massachusetts, United States

Dana Farber Cancer Institute Site Number : 8400101

Boston, Massachusetts, United States

Duke University Medical Center Site Number : 8400008

Durham, North Carolina, United States

Tennessee Oncology, PLLC Site Number : 8400006

Nashville, Tennessee, United States

Mary Crowley Cancer Research Center Site Number : 8400003

Dallas, Texas, United States

Investigational Site Number : 0360002

Heidelberg West, Victoria, Australia

Investigational Site Number : 0360001

Melbourne, Victoria, Australia

Investigational Site Number : 0560001

Leuven, , Belgium

Investigational Site Number : 1240003

Calgary, Alberta, Canada

Investigational Site Number : 1240001

Toronto, Ontario, Canada

Investigational Site Number : 1240002

Montreal, Quebec, Canada

Investigational Site Number : 2330001

Tallinn, , Estonia

Investigational Site Number : 2500002

Marseille, , France

Investigational Site Number : 2500003

Nantes, , France

Investigational Site Number : 2500005

Nantes, , France

Investigational Site Number : 2500001

Villejuif, , France

Investigational Site Number : 2760001

Essen, , Germany

Investigational Site Number : 2760003

Hanover, , Germany

Investigational Site Number : 3800003

Rozzano, Milano, Italy

Investigational Site Number : 3800001

Milan, , Italy

Investigational Site Number : 3800002

Milan, , Italy

Investigational Site Number : 5280001

Rotterdam, , Netherlands

Investigational Site Number : 5280002

Utrecht, , Netherlands

Investigational Site Number : 4100001

Seoul, Seoul-teukbyeolsi, South Korea

Investigational Site Number : 4100002

Seoul, Seoul-teukbyeolsi, South Korea

Investigational Site Number : 7240002

Barcelona, Barcelona [Barcelona], Spain

Investigational Site Number : 7240001

Barcelona, Barcelona [Barcelona], Spain

Investigational Site Number : 7240003

Madrid / Madrid, Madrid, Comunidad de, Spain

Investigational Site Number : 7240004

Madrid / Madrid, Madrid, Comunidad de, Spain

Investigational Site Number : 7240005

Pamplona, Navarre, Spain

Investigational Site Number : 1580002

Tainan City, , Taiwan

Investigational Site Number : 8260001

Glasgow, Central Bedfordshire, United Kingdom

Investigational Site Number : 8260002

Cardiff, Vale of Glamorgan, the, United Kingdom

Countries

United States; Australia; Belgium; Canada; Estonia; France; Germany; Italy; Netherlands; South Korea; Spain; Taiwan; United Kingdom

References

Baranda JC, Robbrecht D, Sullivan R, Doger B, Santoro A, Barve M, Grob JJ, Bechter O, Vieito M, de Miguel MJ, Schadendorf D, Johnson M, Pouzin C, Cantalloube C, Wang R, Lee J, Chen X, Demers B, Amrate A, Abbadessa G, Hodi FS. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFbeta inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study. Clin Transl Sci. 2024 Jun;17(6):e13854. doi: 10.1111/cts.13854.

Reference Type: RESULT

PMID: 38898592 (View on PubMed)

Greco R, Qu H, Qu H, Theilhaber J, Shapiro G, Gregory R, Winter C, Malkova N, Sun F, Jaworski J, Best A, Pao L, Hebert A, Levit M, Protopopov A, Pollard J, Bahjat K, Wiederschain D, Sharma S. Pan-TGFbeta inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade. Oncoimmunology. 2020 Sep 13;9(1):1811605. doi: 10.1080/2162402X.2020.1811605.

Reference Type: DERIVED

PMID: 33224628 (View on PubMed)

Other Identifiers

TCD14678

Identifier Type: OTHER

Identifier Source: secondary_id

U1111-1187-5425

Identifier Type: REGISTRY

Identifier Source: secondary_id

2018-001113-32

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

TCD14678

Identifier Type: -

Identifier Source: org_study_id